



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

30 January 2018  
EMA/HMPC/120986/2018  
Inspections, Human Medicines Pharmacovigilance & Committees Division

## Work plan for the HMPC Quality Drafting Group (Q DG) 2018

Chair	Status
L. Anderson	Final

### 1. Meetings scheduled for 2018

Meeting dates: 22 February, 19 April, 21 June, 06 September, 11 October and 13 December

One face-to-face meeting will be organised in February 2018, other meetings will be held virtually.

### 2. New guidance documents

- Reflection paper on the use of new analytical methods for the quality control of herbal medicinal products.

*Action:* Publication of reflection paper taking into account comments on the concept paper published in 2017

- Guidance on the control of pyrrolizidine alkaloids (PAs) and polycyclic aromatic hydrocarbons (PAHs) in herbal medicinal products.

*Action:* Check existing quality guidance documents (including GACP and specification guidelines) for necessary updates and initiate subsequent revisions and/or draft Q&A.

- Consideration of the implications of ICH Q3D for herbal medicinal products

*Action:* Development of Q&A, as appropriate; consider implications for existing guidelines

### 3. Update, extension or revision of existing guidance documents

- Revision of the Guideline on quality on herbal medicinal products



*Action:* Publication of the draft revised guideline for consultation after coordination with QWP/CHMP and CVMP.

- Revision of the Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and HMP/THMPs.

*Action:* Publication of the draft revised guideline for consultation after coordination with QWP/CHMP and CVMP.

- Update/revision of questions & answers on quality of herbal medicinal products (EMA/HMPC/41500/2010).

*Action:* (1) review and add new Q&A following revision of the quality and specifications guideline, quality assessors training 2015 (skip testing, stability, GACP/GMP, assay and markers; microbiological issues), and reflection paper on microbiological aspects; (2) remove redundant Q&A taken into account for revised guidelines.

- Review of the Reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products.

*Action:* Review for suitability vis-a-vis Ph. Eur. definitions and HMPC monographs/assessment reports with focus on definitions.

#### **4. Coordination with EDQM**

- Development and review of pharmacopoeial monographs and general chapters, methods and notices (including PAs, essential oils, assay methods).

*Action:* On-going activity, selection and discussion of relevant topics for the HMPC via participation of an EDQM representative in Q DG meetings and Q DG members in Ph. Eur. expert groups 13A (K. Reh), 13B (K. Reh) and TCM (R. Laenger). If necessary additional participation on specific items.

#### **5. General**

- Provide input to general quality guidelines and other guidance documents applicable to herbal substances/preparations/medicinal products.

*Action:* On-going activity, monitor QWP activities and draft/propose to HMPC input as necessary.

- Provide input on quality questions for herbal medicinal products in the framework of HMPC coordination with other EMA committees/working parties (e.g. SA procedures with SAWP) if required.